Every 10-Q that Viemed Healthcare, Inc. (VMD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow VMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VMD filings page.
Viemed Healthcare, Inc. reported Q2 2026 revenue of 78,097 thousand USD, up 23.9% from 63,056 thousand a year earlier, driven by growth in ventilator rentals, other home medical equipment, and equipment and supply sales, including contributions from the Lehan Drugs acquisition.
Gross profit rose to 45,048 thousand USD, but income from operations slipped to 4,461 thousand and net income attributable to Viemed decreased to 2,764 thousand, with diluted EPS of 0.07 versus 0.08. Adjusted EBITDA was 13,715 thousand, as higher selling, general and administrative costs and losses on asset disposals weighed on margins.
For the first six months of 2026, net cash provided by operating activities increased to 23,973 thousand USD, funding 15,172 thousand of capital expenditures and continued debt reduction. Debt under the 2022 Senior Credit Facilities declined to 7,445 thousand, cash ended at 10,680 thousand, and total assets reached 204,224 thousand.
Viemed Healthcare, Inc. reported strong top-line growth for the quarter ended March 31, 2026. Revenue rose to $75.4 million from $59.1 million, driven by broader rental activity and a sharp increase in equipment and supply sales.
Ventilator rentals generated $35.4 million and other home medical equipment rentals $16.2 million, while equipment and supply sales more than doubled to $17.5 million, aided by women’s health products and the Lehan Drugs acquisition. Gross margin was 56.8%, slightly above last year.
Net income attributable to Viemed was $2.6 million, essentially flat year over year, with diluted EPS of $0.06. Operating cash flow improved to $8.1 million, supporting $6.7 million of capital spending and $3.2 million of debt repayment. Cash ended at $9.8 million and total debt at $9.6 million, with shareholders’ equity of $145.8 million.
Viemed Healthcare (VMD) reported Q3 results showing continued top-line growth alongside active capital deployment. Revenue reached $71.9 million, up from $58.0 million a year ago, driven by ventilator rentals and expanding equipment sales and services. Gross profit was $41.3 million versus $34.4 million. Net income attributable to the company was $3.5 million (diluted EPS $0.09) compared with $3.9 million (EPS $0.10) last year as operating costs rose with growth and integration.
Year-to-date, revenue totaled $194.1 million vs. $163.6 million, and diluted EPS was $0.23 vs. $0.17. Operating cash flow was strong at $33.5 million. The company closed the Lehan Drugs acquisition on July 1 for $28.7 million, adding goodwill of $25.5 million. Debt increased under the 2022 facilities to $21.1 million from $4.6 million at year-end, while cash ended the quarter at $11.1 million. Viemed repurchased 1,976,441 shares for $13.6 million under its 2025 program, reducing the quarter-end share count to 38,017,907. On October 29, the company repaid $5.0 million on its revolver.